Vaxcyte (PCVX) Enterprise Value (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Enterprise Value data on file, last reported at -$1.7 billion in Q1 2026.

• On a quarterly basis, Enterprise Value fell 3.91% year-over-year to -$1.7 billion in Q1 2026; TTM through Mar 2026 was -$1.7 billion, a 3.91% decrease from a year earlier, with the FY2025 full-year figure at -$1.6 billion, up 10.66% from the prior year.
• Enterprise Value for Q1 2026 stood at -$1.7 billion, down from -$1.6 billion in the prior quarter.
• Over the last five years, Enterprise Value for PCVX reached as high as -$334.6 million in Q1 2022 and fell as low as -$2.2 billion in Q3 2024.
• Historically, Enterprise Value has averaged -$1.3 billion across 5 years, with a median of -$1.5 billion in 2024.
• Across the five-year window, Enterprise Value slumped 278.65% in 2022 and grew 21.52% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$931.4 million in 2022, then decreased by 15.98% to -$1.1 billion in 2023, then sank by 61.74% to -$1.7 billion in 2024, then grew by 10.66% to -$1.6 billion in 2025, then fell by 11.29% to -$1.7 billion in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$1.7 billion in Q1 2026, -$1.6 billion in Q4 2025, and -$1.7 billion in Q3 2025.